Lactate Like Fluconazole Reduces Ergosterol Content in the Plasma Membrane and Synergistically Kills Candida albicans

Jakub Suchodolski 1, Jakub Muraszko 1*, Przemysław Bernat 2* and Anna Krasowska 1,*

1 Department of Biotransformation, Faculty of Biotechnology, University of Wroclaw, 50-383 Wroclaw, Poland; jakub.suchodolski@uwr.edu.pl (J.S.); jakub.muraszko@gmail.com (J.M.)
2 Department of Industrial Microbiology and Biotechnology, Faculty of Biology and Environmental Protection, University of Lodz, 90-237 Lodz, Poland; przemyslaw.bernat@biol.uni.lodz.pl

* Correspondence: anna.krasowska@uwr.edu.pl

Abstract: Candida albicans is an opportunistic pathogen that induces vulvovaginal candidiasis (VVC), among other diseases. In the vaginal environment, the source of carbon for C. albicans can be either lactic acid or its dissociated form, lactate. It has been shown that lactate, similar to the popular antifungal drug fluconazole (FLC), reduces the expression of the ERG11 gene and hence the amount of ergosterol in the plasma membrane. The Cdr1 transporter that effluxes xenobiotics from C. albicans cells, including FLC, is delocalized from the plasma membrane to a vacuole under the influence of lactate. Despite the overexpression of the CDR1 gene and the increased activity of Cdr1p, C. albicans is fourfold more sensitive to FLC in the presence of lactate than when glucose is the source of carbon. We propose synergistic effects of lactate and FLC in that they block Cdr1 activity by delocalization due to changes in the ergosterol content of the plasma membrane.

Keywords: Candida albicans; lactate; fluconazole; ergosterol; Cdr1

1. Introduction

Candida spp. are opportunistic pathogens that cause severe systemic infections in humans, such as vulvovaginal candidiasis (VVC) [1]. The main etiological species contributing to vaginal infections are Candida albicans (around 50%) and Candida glabrata (15–25%) [2,3]. Approximately 75% of women suffer from VVC at least once during their lifetime, and in many cases from recurrent VVC (RVVC) [4,5].

One of the factors defending the vagina against fungal infection is the presence of probiotic Lactobacillus spp. bacteria, which produce various short-chain aliphatic organic acids, such as lactic or acetic acid [6,7]. The concentration of acetic acid in the vaginal environment is low, ranging from 1–4 mM [8], while the lactic acid concentration in the vaginal milieu is around 110 mM [9]. Based on their results, Matsubara et al. [10] suggested that an antifungal effect occurs only after prolonged incubation with cultures of Lactobacilli (24 or 48 h) in which lactic acid could have accumulated in the medium at the right quantity. Other researchers have observed that the lactic acid concentration in the vaginal tract is too low to prevent the growth of all Candida spp. and that low pH plays a minor role in Candida spp. infections [11,12].

Despite these unfavorable facts, the presence of lactic acid increases the susceptibility of C. albicans to the antifungal compound fluconazole (FLC) [13]. Recently, Lourenco et al. [14] described a synergistic, reducing effect of lactic acid and FLC against C. albicans, but this effect was observed only in concentrations of lactic acid above 80 mM. Moreover, C. albicans growing on lactate is more resistant to amphotericin B (AmB), another antifungal drug [15]. The target for both antifungals is ergosterol that is present in the fungal membranes. FLC blocks the synthesis of ergosterol, while AmB binds to ergosterol and disturbs its functions in the membrane [16,17]. The reaction of Candida spp. to both antifungotics in the presence of lactic acid varies but indicates the role of ergosterol in these processes of resistance.
The mechanism of resistance of *C. albicans* to FLC consists mainly in the efflux of this compound by three membrane transporters, namely, Cdr1, Cdr2, and Mdr1. It was previously found that the type of carbon source affects the resistance of *C. albicans* to FLC [18]. Interestingly, the expressions of both CDRS and MDR1 were decreased when the cells were grown on either glycerol or acetate compared with those grown on glucose [19]. Furthermore, Mira et al. [20] observed that the effect of undissociated organic acids on yeast cells is due to the perturbation of the plasma membrane (PM) structure, which can thus facilitate the introduction of the azole drug. Moreover, our research indicates a strong effect of changes to the lipid composition of the PM during resistance of *C. albicans* to azole compounds [21–23].

Acidic environments favor the existence of an undissociated form of lactic acid. Many previous studies have reported an absence of lactic acid toxicity against *C. albicans* at acidic pH [24,25], which could result from the ability to rapidly use lactic acid for metabolism [14]. As a Crabtree-negative organism, *C. albicans* can utilize glucose together with other carbon sources such as organic acids at the same time [26,27]. Therefore, when it uses lactic acid, it will prevent the acidification of its environment [12]. In a pH closer to neutral, a dissociated form of lactic acid, namely, lactate, prevails and can inhibit the growth of *C. albicans*. Despite these promising recent results, the influence of lactic acid and lactate on the tolerance of *Candida* spp. to azole compounds is still poorly understood.

In this work, we observed the increased sensitivity of *C. albicans* to FLC in the presence of lactate. We also explain the mechanism of inhibition of Cdr1 transporter activity by the lactate-dependent reduction of ergosterol in the PM. Hence, we propose that the mechanism of influence of lactate on the activity of Cdr1 transporters is based on our previous observations regarding ergosterol’s impact on membrane transporters [21].

2. Results

2.1. Lactate Affects the Resistance of *C. albicans* to Fluconazole Depending on Ergosterol—The First Observations

Both lactic acid and lactate can interact with *Candida* spp. depending on the pH of the vaginal environment [12]. Information regarding the mechanism by which lactate exerts its effects on *C. albicans* cells is scarce; hence we decided to investigate the susceptibility of *C. albicans* to FLC. This compound is effluxed from cells by PM CDRS transporters, mainly Cdr1 or Cdr2, in an auxiliary manner [28]. Our results show that when lactate is the sole carbon source, both the parental and mutant strains that have either one or both CDRS transporters removed are fourfold more sensitive to FLC than when they grow in the presence of glucose (Table 1). The absence of a difference in the sensitivity of *C. albicans* to FLC between the parental strain and the mutant with deletion in the *CDR2* gene indicates activity of only Cdr1p under the conditions utilized.

| Strain *C. albicans* | Medium | Fluconazole (µg/mL) | Brefeldin A (µg/mL) | Fluphenazine (µg/mL) |
|----------------------|--------|---------------------|---------------------|----------------------|
| WT                   | YPD    | 2                   | 16                  | >125                 |
|                      | YPL    | 0.5                 | 32                  | >250                 |
| *cdr1Δ*              | YPD    | 0.25                | 4                   | 125                  |
|                      | YPL    | 0.063               | 4                   | 250                  |
| *cdr2Δ*              | YPD    | 2                   | 16                  | 125                  |
|                      | YPL    | 0.5                 | 32                  | >250                 |
| *cdr1Δcdr2Δ*         | YPD    | 0.25                | 4                   | 62.5                 |
|                      | YPL    | 0.063               | 4                   | 62.5                 |
The use of brefeldin A and fluphenazine, which are substrates of Cdr1, did not induce a higher sensitivity of \textit{C. albicans} in the presence of lactate compared with glucose as a carbon source (Table 1).

Brefeldin A is an inhibitor of LDH-mediated cholesterol efflux \cite{29}, whereas fluphenazine is a calmodulin antagonist \cite{21}. Both compounds do not interact with the cell membrane or ergosterol. Based on the obtained results, we assumed that lactate could affect \textit{C. albicans} synergistically with FLC by altering the amount of ergosterol in the PM and, for this reason, reduce the activity of Cdr1p. We decided to test the above hypothesis by carrying out further experiments.

2.2. Cdr1 Transporter Activity and CDR1 Gene Expression Are More Efficiently Upregulated in the Presence Lactate Compared with Glucose

Cdr transporters are constitutively produced PM proteins that efflux xenobiotics from \textit{C. albicans} cells, hence protecting them from death. Cdr1p activity varies depending on the growth phase of \textit{C. albicans} and the presence of different compounds in the environment \cite{21}. In the presence of lactate, the activity of Cdr1 was about 0.8- and 3-fold higher than when glucose was present, depending on the growth phase (Figure 1), and the reverse was also observed when lactate was the sole carbon source. In the late logarithmic phase of \textit{C. albicans} growth with glucose-only media, Cdr1p activity decreased, while on lactate its activity significantly increased (Figure 1).

\begin{figure}[h]
\centering
\includegraphics[width=\textwidth]{figure1.png}
\caption{Cdr1p-dependent rhodamine 6G (R6G) efflux in \textit{C. albicans} CAF2-1 strain during growth (8 and 14 h) in YPD (glucose) and YPL (lactate) media. The data are presented as normalized (=1 for 8 h YPD-grown strain) fluorescence intensity of extracellular R6G (mean ± SD, n = 3). Statistical analysis compared data during different growth phases (above lines) or compared YPD- and YPL-grown strains (above bars) (*, $p < 0.05$; ***, $p < 0.001$).}
\end{figure}

During the growth of \textit{C. albicans} in the presence of lactate, not only did the activity of Cdr1p increase, but the amount of this protein significantly increased when visualized by Western blot (Figure 2A). The expression of the \textit{CDR1} gene encoding this transporter was also higher, especially following 14 h of \textit{C. albicans} growth (Figure 2B).

2.3. Lactate Accelerates Delocalization of Cdr1 Transporter from PM into Vacuoles

To explain why there was a high sensitivity of \textit{C. albicans} to FLC observed when grown in the presence of lactate despite an increase in Cdr1 expression and activity, we examined the localization of Cdr1p in the cells. It seems that in 8 h in a large amount, Cdr1p already delocalizes from the PM to vacuoles in the presence of lactate. When the source of carbon is glucose, Cdr1p mostly has the correct localization in the PM following 8 h of culture (Figure 3). In the late logarithmic phase (14 h), Cdr1p can be found in both the PM and vacuoles independent of the carbon source being utilized (Figure 3).
Figure 2. (A) Immunoblot analysis of Cdr1p levels in C. albicans ASCa1 (CDR1-GFP) strain during growth (8 and 14 h) in YPD (glucose) or YPL (lactate). The samples were resolved using 6% SDS-PAGE and probed with an anti-GFP antibody. Ponceau S staining was used as the loading control. The experiment was a representative of three independent assays, and the presented conditions were resolved in the same gel and cut out into separate lines (Figure S1 in Supplementary Materials). (B) Relative CDR1 gene expression in C. albicans during different growth phases (8 and 14 h) in YPD or YPL medium. Gene expression levels are represented as mean $2^{-\Delta\Delta CT}$ values $\pm$ SD ($n = 6$) normalized to 1 for 8 h YPD-grown gene expression level. Statistical analysis compared YPD- and YPL-grown strains (***, $p < 0.001$).

Figure 3. Confocal micrographs of vacuolar membrane staining (FM 4-64) and subcellular localization of CDR1-GFP protein in C. albicans ASCa1 (CDR1-GFP) strain during growth (8 and 14 h) in YPD (glucose) or YPL (lactate) medium. A merged image of the GFP-tagged protein and FM 4-64 staining is shown in the third and sixth columns. Scale bar = 5 µm.

2.4. Lactate Inhibits Ergosterol Synthesis in C. albicans Cells

One of the reasons for the delocalization of Cdr1p from the PM to inside cells may be changes in the lipid composition of the membrane and mainly the loss of ergosterol [21]. The growth of C. albicans when lactate was the sole carbon source was significantly weaker than the growth in the presence of glucose (Figure 4A). When a mutant strain of C. albicans
without ergosterol was cultured on lactate instead of glucose, we found that there was no growth present (Figure 4B).

Figure 4. (A) Growth curves of *C. albicans* CAF2-1 strains in YPD (glucose) or YPL (lactate) medium (28 °C, 120 rpm), represented as OD$_{600}$ (means ± SD, n = 4). (B) Growth phenotypes of *C. albicans* CAF2-1 (parental strain) and KS028 (*erg11*Δ/Δ) strains after 48 h incubation at 28 °C in YPD or YPL medium.

The intensity of the inhibition of ergosterol synthesis by FLC varies depending on the growth phase of *C. albicans* [30]. Thus, we investigated how high the expressions of the *ERG3* and *ERG11* genes are following 8 and 14 h *C. albicans* culture in the presence of lactate. Both genes are crucial in the sterol synthesis pathway in *C. albicans* [31]. Lactate inhibited the expression of *ERG11* by approximately 10-fold more than glucose following 8 h growth of *C. albicans*, while *ERG3* gene expression was similarly low in both phases of growth regardless of the carbon source (Figure 5).

The *ERG11* gene encodes lanosterol demethylase, which converts lanosterol into 4,4-dimethyl-5-cholesta-8,14,24-trien-3-ol, and the *ERG3* gene encodes C5 sterol desaturase, which converts episterol into 5,7,24(28)-ergostadienol in the ergosterol biosynthesis pathway [31]. As a result of the decrease in the expression of these genes, toxic sterols can accumulate in the membrane, which replace the missing ergosterol [32]. Deletion of both *ERG11* and *ERG3* genes leads to accumulation of eburicol and 14-α-methylfecosterol [33]. Analysis of sterols in *C. albicans* cells growing in the presence of lactate or glucose showed that in both 8 h and 14 h culture conditions, there was less (1.7-fold and 3.6-fold, respectively) ergosterol when cultured in lactate than in glucose (Table 2). For cells growing in the presence of lactate, 4-methylfecoosteral was detected and in smaller amounts ergostadienol and 4,4-dimethylcholesta-8,24-dien-3b-ol, which were not found in cells cultured in the presence of glucose (Table 2). Lanosterol was at its highest level in cells grown on glucose as a source of carbon following 8 h of culture, while in other samples, lanosterol remained at a similar level (Table 2).
Table 2. Sterols (µg/mg dry mass of isolated lipids, means ± SD, n = 3) in C. albicans CAF2-1 grown in YPD (glucose) or YPL (lactate) for 8 or 14 h. ND—not detected. Statistical analysis was performed in accordance with µg/mg values after 8 h of glucose culture (**, p < 0.01; ***, p < 0.001).

|                  | Glucose   | Lactate   |
|------------------|-----------|-----------|
| Ergosterol       | 39.1 ± 2.3 | 65.2 ± 1.1*** | 22.9 ± 0.3** | 17.8 ± 4.8*** |
| Lanosterol       | 8.5 ± 0.2  | 5.4 ± 0.6**  | 5.9 ± 0.5** | 5.1 ± 0.8*** |
| 4-methylfucosterol| ND       | ND        | 3.9 ± 0.5  | 3.9 ± 0.2  |
| Ergosta-5,7-dienol| ND       | ND        | 1.1 ± 0.1  | 0.8 ± 0.2  |
| 4,4-dimethylcholesta-8,24-dien-3b-ol | ND | ND | 1.3 ± 0.3 | 1.1 ± 0.1 |
| Total sterols    | 47.6 ± 2.5 | 70.6 ± 1.7*** | 35.1 ± 1.7 | 28.7 ± 6.1** |

3. Discussion

Increasingly, research shows that the activities of antimicrobial drugs are strictly dependent on natural conditions that prevail in the environment of microbes [34,35]. Candidiasis treatment is no exception in this case, and it is important to take into consideration the effects of compounds that naturally occur in niches where C. albicans is present in the body. Recently, our research showed that fructose activates Mdr1 and Cdr1 transporters in C. albicans in response to the presence of FLC [18]. Furthermore, we demonstrated that capric acid produced by probiotic yeast Saccharomyces boulardii influences the susceptibility
of C. albicans to FLC and AmB [23]. Lactate, a dissociated form of lactic acid, can occur in the vaginal environment when C. albicans rapidly absorbs lactic acid and the pH of the environment is raised [14]. This occurs when appropriate strains of Lactobacillus multiply in the microbiome of the vagina [12]. Lactobacillus and thus lactate or lactic acid may also be applied from the outside during treatment of candidiasis [36]. Our results presented herein indicate higher efficacy of candidiasis treatment when both lactate and FLC are used. We demonstrate that lactate lowers the expression of the ERG11 gene of the ergosterol biosynthesis pathway in the early hours of C. albicans culture and induces incorrect localization of Cdr1, a transporter that removes FLC from cells (Figures 3 and 5). According to our results, C. albicans increases CDR1 gene expression and Cdr1p activity, as measured by R6G efflux, in the presence of lactate when compared with glucose, mostly in the late logarithmic phase of growth (Figures 1 and 2). The time difference between inhibition of ergosterol synthesis and delocalization of Cdr1p from PM (8 h) and Cdr1p overproduction (14 h) appears too long for the cell to effectively defend itself against stress. This is also evidenced by accelerated growth of C. albicans on lactate compared with glucose (Figure 4A).

Analysis of sterols in the PM of cells growing in the presence of lactate showed a loss of the total amount of sterols in the membrane compared with cells growing on glucose. This was independent of the presence of new types of sterols (Table 2). In the study of Suchodolski et al. [21], the authors demonstrated that in the PM of the mutant C. albicans without ergosterol, there was an increase in the amount of sterols not normally present, particularly lanosterol, to compensate for the lack of ergosterol. In this work, we did not observe such compensation; hence the overall level of sterols was low in C. albicans that grew in the presence of lactate (Table 2). The C. albicans mutant with deletion of the ERG11 gene did not grow on lactate (Figure 4B), and it can be assumed that lactate can also block cell defense after a complete loss of ergosterol.

We conclude that the synergistic effects of lactate and FLC are based on a similar mechanism of influence on C. albicans. Both compounds block the synthesis of ergosterol and cause delocalization of Cdr1p from the PM in the early hours of C. albicans growth. Cells cannot therefore efflux FLC; hence it has a fourfold lower MIC in this case (Table 1). The research of such interactions as we describe herein can help to improve the treatment of candidiasis and other diseases.

4. Materials and Methods

4.1. Reagents

The reagents used in this study were purchased from the following sources: 2-deoxy-D-glucose, fluconazole (FLC), rhodamine 6G (R6G), fluphenazine, β-mercaptoethanol (BME), ethylenediaminetetraacetic acid (EDTA), cholesterol, and BSTFA–TMCS (n,O-bis(trimethylsilyl) trifluoroacetamide/trimethylchlorosilane) (Sigma-Aldrich, Poznań, Poland). The following commercial antibodies were also used: a mouse monoclonal anti-GFP (Roche; distributor: Sigma-Aldrich, Poznań, Poland) and HRP-conjugated rabbit anti-mouse (GE Healthcare; distributor: Sigma-Aldrich, Poznań, Poland). D-glucose, bacteriological agar, zymolyase, D-sorbitol, brefeldin A (Bioshop; distributor: Lab Empire, Rzeszów, Poland), peptone, yeast extract (YE) (BD; distributor: Diag-Med, Warszawa, Poland), chloroform (CHCl3), methanol (MetOH), lactate (Chempur, Piekary Śląskie, Poland), FM 4-64 dye (Thermo Fisher, Warszawa, Poland). All reagents were analytical-grade compounds.

4.2. Strains and Growth Conditions

The C. albicans strains used in this study are listed in Table 3. CAF2-1, DSY448, DSY653, and DSY654 were gifts from Professor D. Sanglard (Lausanne, Switzerland). ASCa1 and KS028 were previously generated in our laboratory. Strains were maintained at 28 °C on YPD (1% YE, 1% peptone, 2% glucose) or YPL (1% YE, 1% peptone, 2% lactate) medium in a shaking incubator (120 rpm). Agar at a final concentration of 2% was used for solidifying the medium. For most of the experiments, cells were grown in 20 mL of YPD or YPL medium at 28 °C, shaking at 120 rpm with a starting A600 = 0.1. Cells were incubated until
they reached the early (8 h) or late (14 h) logarithmic phase. Cells were then centrifuged at 4500 rpm for 5 min, washed twice with either phosphate-buffered saline (PBS) or 50 mM HEPES–NaOH buffer (pH 7.0), and resuspended in either PBS or HEPES–NaOH to the target A₆₀₀.

Table 3. C. albicans strains used in the study.

| Strain    | Genotype                                 | Reference |
|-----------|------------------------------------------|-----------|
| CAF2-1    | ura3Δ::imm434/URA3                       | [37]      |
| DSY448    | ura3Δ::imm434/ura3Δ::imm434              | [38]      |
| DSY653    | cdr1Δ::hisG/cdr1Δ::hisG-URA3::hisG      | [39]      |
| DSY654    | cdr2Δ::hisG/cdr2Δ::hisG-URA3::hisG      | [39]      |
| ASCa1     | ura3Δ::imm434/ura3Δ::imm434              | [40]      |
| KS028     | erg11Δ::SAT1-FLIP/erg11Δ::FRT           | [21]      |

4.3. MIC₅₀ Determination

Experiments were performed in compliance with the Clinical and Laboratory Standards Institute (2008), 3rd ed. M27-A3, with modifications described previously [21]. Briefly, the MIC₅₀ was determined by serial dilution of FLC, brefeldin A, or fluphenazine in YPD or YPL medium using sterile 96-well plates (Sarstedt, Stare Babice, Poland) and then inoculated with CAF2-1 cells at a final A₆₀₀ of 0.01. After incubating at 28 °C for 24 h, A₆₀₀ was again measured (ASYS UVM 340, Biogenet Józefów, Poland). The MIC₅₀ was determined by normalizing the control A₆₀₀ (without antimicrobial agents) as 100%.

4.4. Microscopic Studies

ASCa1 strain (CDR1-GFP), grown in YPD or YPL, was washed with PBS, concentrated by suspending the pellets in lower volume of PBS, and observed under a Leica SP8 LSM microscope (Leica Microsystems, Wetzlar, Germany). The staining of vacuolar membranes was performed with FM 4-64 dye as described previously [41].

4.5. Western Blot

Crude protein extract from ASCa1 strain was isolated as previously described [21,42]. Electrophoretic separation and transfer of Cdr1p-GFP was also performed as previously described [42]. For detection, a monoclonal mouse anti-GFP primary antibody was used, followed by an HRP-conjugated rabbit anti-mouse secondary antibody [18]. The remaining steps were performed as described [42].

4.6. Real-Time PCR

The isolation of RNA from C. albicans suspensions and cDNA synthesis was performed as previously described [43]. Briefly, total RNA from C. albicans cells was isolated using a Total RNA Mini kit provided by A&A Biotechnology (Gdynia, Poland). RNA was eluted with 18H₂O. cDNA was obtained using a High-Capacity cDNA Reverse Transcription Kit (Thermo Fisher Scientific, Waltham, MA, USA). Then, samples were used as a matrix in quantitative PCR reaction. Gene expression levels were measured by quantitative PCR, which was performed with an iTaq Universal SYBR Green Supermix kit (Bio-Rad, Warszawa, Poland). Reactions were run using the StepOne Real-Time PCR System (Thermo Fisher Scientific, Waltham, MA, USA). Gene expression calculations were performed using the formula 2⁻ΔΔCT, with the RDN18 gene as internal control, according to the protocol of Szczepaniak et al. [40]. The following gene-specific primers were used: RDN18F and RDN18R, ERG11F and ERG11R, ERG3F and ERG3R, CDR1F and CDR1R (Table 4).
Table 4. Primers used in the study.

| Primer | Sequence 5′–3′ |
|--------|----------------|
| RDN18F | AGAAACGGCTACCACATCCAA |
| RDN18R | GGGCCCTGTATCGTTATTTATTGT |
| ERG11F | TTTCCTGAGATGGTAGACATA |
| ERG11R | GAACTATAATCAGGGTCAGG |
| ERG3F  | CCATCATGAATCATGACAGTCC |
| ERG3R  | TGCTTCTCATGCTTTCCATC |
| CDR1F  | TTTAGCCAGAACTTTCACTCATGATT |
| CDR1R  | TATTTATTTCTTCATGTTCATATGGATTGA |

4.7. Efflux Activity of Cdr1 Transporter

Suspensions of CAF2-1, in 25 mL HEPES–NaOH ($A_{600} = 1.0$), were grown in YPD or YPL medium with 2-deoxy-D-glucose and stained with R6G as previously described [18]. In each of the conditions, the R6G uptake was estimated to be $\geq 95\%$. Fluorescence intensities (FI) were collected 15 min after the initiation of the R6G efflux, and the efflux activity of CAF2-1 cells, grown in YPD, was normalized to 1.

4.8. Phenotype Assay

CAF2-1 and KS028 strain suspensions (PBS, $A_{600} = 0.7$, prepared from overnight YPD or YPL cultures) were serially diluted to $10^{-3}$. An amount of 2 µL was spotted onto either YPD or YPL agar, cultivated for 48 h at 28 °C. The plates were photographed using a FastGene® B/G GelPic imaging box (Nippon Genetics, Tokyo, Japan).

4.9. PM Isolation and Sterol Analysis

PMs were isolated from suspensions of CAF2-1 grown in YPD or YPL medium (PBS, concentrated to $A_{600} = 20$) as previously described [21]. Briefly, cells were resuspended in lysis medium (1 M sorbitol, 0.1 M EDTA, 1% BME, 3 mg/mL zymolyase) and incubated at 37 °C for 30 min. Protoplasts were then washed with 1.2 M sorbitol, lysed with ice-cold $d_2$H$_2$O shock, and disrupted by sonication (5 s cycles for 2 min at 4 °C) using an ultrasonic processor (SonicVibra-Cell VCX 130, Sonics, Newtown, CT, USA). Cell lysate was centrifuged at 10,000 rpm at 4 °C for 10 min to remove unbroken material, and the supernatant was ultracentrifuged at 100,000 rpm at 4 °C for 60 min using a Micro Ultracentrifuge CS150FNX (Hitachi, Tokyo, Japan). The crude PM pellets were suspended in a chloroform–methanol solution (1:2 v/v). The chloroform layer was concentrated using nitrogen gas after vigorous stirring at 4 °C for 16 h. PM fractions were separated with BSTFA–TMCS, and sterol analysis was performed by gas chromatography–mass spectrometry (GC–MS) with cholesterol as an internal standard following the previously described protocol [21,44].

4.10. Statistical Analyses

Data represent the means ± standard deviation (± SD) from at least three independent replicates for each experiment. The exceptions were microscopic observations and Western blot analyses, which were performed in at least two independent replicates, of which representative images were included in the figures. Statistical significance was determined using Student’s $t$-test (binomial, unpaired), and a $p$-value of <0.05 was considered significant.

**Supplementary Materials:** The following are available online at https://www.mdpi.com/article/10.3390/ijms22105219/s1, Figure S1: Immunoblot analysis of Cdr1p levels in C. albicans ASCa1 (CDR1-GFP) strain during growth (8 and 14 h) in YPD (glucose) or YPL (lactate). The samples were resolved using 6% SDS-PAGE and probed with an anti-GFP antibody. Ponceau S staining was used as the loading control.
Author Contributions: Conceptualization, J.S. and A.K.; methodology and investigation, J.S., J.M., P.B. and A.K.; funding, writing—original draft preparation, editing, and supervision, A.K. All authors have read and agreed to the published version of the manuscript.

Funding: This work was supported by the National Science Centre, Poland, NCN Grant 2016/23/B/ NZ1/01928 (A.K.).

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Data Availability Statement: The data presented in this study are available on request from the corresponding author (A.K.).

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Sobel, J. Vulvovaginal candidosis. Lancet 2007, 369, 1961–1971. [CrossRef]
2. Ahmad, K.; Kokosar, J.; Guo, X.; Gu, Z.; Ishchuk, O.; Piskur, J. Genome structure and dynamics of the yeast pathogen Candida glabrata. FEMS Yeast Res. 2014, 14, 529–535. [CrossRef]
3. Brunke, S.; Hube, B. Two unlike cousins: Candida albicans and C. glabrata infection strategies. Cell. Microbiol. 2013, 15, 701–708. [CrossRef][PubMed]
4. Goncalves, B.; FeErreira, C.; Alves, C.; Henriques, M.; Azeredo, J.; Silva, S. Vulvovaginal candidiasis: Epidemiology, microbiology and risk factors. Crit. Rev. Microbiol. 2016, 42, 905–927. [CrossRef]
5. Sobel, J. Recurrent vulvovaginal candidiasis. Am. J. Obstet. Gynecol. 2016, 214, 15–21. [CrossRef]
6. Boris, S.; Barbes, C. Role played by lactobacilli in controlling the population of vaginal pathogens. Microb. Infect. 2000, 2, 543–546. [CrossRef]
7. Boskey, E.; Telsch, K.; Whaley, K.; Moench, T.; Cone, R. Acid production by vaginal flora in vitro is consistent with the rate and extent of vaginal acidification. Infect. Immun. 1999, 67, 5170–5175. [CrossRef]
8. Owen, D.; Katz, D. A vaginal fluid simulant. Contraception 1999, 59, 91–95. [CrossRef]
9. O’Hanlon, D.; Moench, T.; Cone, R. Vaginal pH and microbicidal lactic acid when lactobacilli dominate the microbiota. PLoS ONE 2013, 8, e80074. [CrossRef][PubMed]
10. Matsubara, V.; Wang, Y.; Bandara, H.; Mayer, M.; Samarayake, L. Probiotic lactobacilli inhibit early stages of Candida albicans biofilm development by reducing their growth, cell adhesion, and filamentation. Appl. Microbiol. Biotechnol. 2016, 100, 6415–6426. [CrossRef]
11. Liu, M.; Xu, S.; He, Y.; Deng, G.; Sheng, H.; Huang, X.; Ouyang, C.; Zhou, H. Diverse vaginal microbiomes in reproductive-age women with vulvovaginal candidiasis. PLoS ONE 2013, 8, e79812. [CrossRef][PubMed]
12. Zhang, I.; Pap, I.; Aspöck, C.; Schüller, C. The role of Lactobacillus species in the control of Candida via biotrophic interactions. Microb. Cell 2020, 7, 1. [CrossRef] [PubMed]
13. Alves, R.; Mota, S.; Silva, S.; Rodrigues, C.; Brown, A.; Henriques, M.; Casal, M.; Paiva, S. The carboxylic acid transporters Jen1 and Jen2 affect the architecture and fluconazole susceptibility of Candida albicans biofilm in the presence of lactate. Biofouling 2017, 33, 943–954. [CrossRef][PubMed]
14. Lourenço, A.; Pedro, N.; Salazar, S.; Mira, N. Effect of acetic acid and lactic acid at low pH in growth and azole resistance of Candida albicans and Candida glabrata. Front. Microbiol. 2019, 9, 3265. [CrossRef]
15. Ene, I.; Adya, A.; Wehmeier, S.; Brand, A.; MacCallum, D.; Gow, N.; Brown, A. Host carbon surces modulate cell wall architecture, drug resistance and virulence in a fungal pathogen. Cell Microbiol. 2012, 14, 1319–1335. [CrossRef]
16. Williams, D.; Lewis, M. Pathogenesis and treatment of oral candidosis. J. Oral Microbiol. 2011, 1, 5771. [CrossRef]
17. Gray, K.; Palacios, D.; Dailey, I.; Endo, M.; Uno, B.; Wilcock, B.; Burke, M. Amphotericin primarily kills yeast by simply binding ergosterol. Proc. Natl. Acad. Sci. USA 2012, 109, 2234–2239. [CrossRef]
18. Suchodolski, J.; Krasowska, A. Fructose induces fluconazole resistance in Candida albicans through activation of Mdr1 and Cdr1 transporters. Int. J. Mol. Sci. 2021, 22, 2127. [CrossRef][PubMed]
19. Lyons, C.; White, T. Transcriptional analyses of antifungal drug resistance in Candida albicans. Antimicrob. Agents Chemother. 2000, 44, 2296–2303. [CrossRef][PubMed]
20. Mira, N.; Teixeira, M.; Sa-Correia, I. Adaptive response and tolerance to weak acids in Saccharomyces cerevisiae: A genome-wide view. Omics J. Integr. Biol. 2010, 14, 525–540. [CrossRef][PubMed]
21. Suchodolski, J.; Muraszko, J.; Bernat, P.; Krasowska, A. A crucial role for ergosterol in plasma membrane composition, localisation, and activity of Cdr1p and H+-ATPase in Candida albicans. Microorganisms 2019, 7, 378. [CrossRef][PubMed]
22. Suchodolski, J.; Muraszko, J.; Korba, A.; Bernat, P.; Krasowska, A. Lipid composition and cell surface hydrophobicity of Candida albicans influence the efficacy of fluconazole–gentamicin treatment. Yeast 2020, 37, 117–129. [CrossRef]
23. Suchodolski, J.; Derkacz, D.; Bernat, P.; Krasowska, A. Capric acid secreted by Saccharomyces boulardii influences the susceptibility of Candida albicans to fluconazole and amphotericin B. Sci. Rep. 2021, 11, 1–10. [CrossRef]
24. Moosa, M.; Sobel, J.; Elhalis, H.; Du, W.; Akins, R. Fungicidal activity of fluconazole against Candida albicans in a synthetic vagina-simulative medium. Antimicrob. Agents Chemother. 2004, 48, 161–167. [CrossRef] [PubMed]
25. Kasper, L.; Miranon, P.; Jablonowski, N.; Wissgott, S.; Wilson, D.; Brunke, S.; Hube, B. Antifungal activity of clotrimazole against Candida albicans depends on carbon sources, growth phase and morphology. J. Med. Microbiol. 2015, 64, 714–723. [CrossRef] [PubMed]
26. Van Ende, M.; Wijnants, S.; Van Dijck, P. Sugar sensing and signaling in Candida albicans and Candida glabrata. Front. Microbiol. 2019, 10, 1–16. [CrossRef] [PubMed]
27. Sandai, D.; Yin, Z.; Selway, L.; Stead, D.; Walker, J.; Leach, M.D.; Bohovych, I.; Ene, I.V.; Kastora, S.; Budge, S.; et al. The Evolutionary Rewiring of Ubiquitination Targets Has Reprogrammed the Regulation of Carbon Assimilation in the Pathogenic Yeast Candida albicans. MBio 2012, 3, e00495-12. [CrossRef] [PubMed]
28. Karababa, M.; Coste, A.; Rognon, B.; Bille, J.; Sanglard, D. Comparison of gene expression profiles of Candida albicans azole-resistant clinical isolates and laboratory strains exposed to drugs inducing multidrug transporters. Antimicrob. Agents Chemother. 2004, 48, 3064–3079. [CrossRef] [PubMed]
29. Niimi, M.; Niimi, K.; Takano, Y.; Holmes, A.; Fischer, F.; Uehara, Y.; Cannon, R. Regulated overexpression of CDR1 in Candida albicans confers multidrug resistance. J. Antimicrob. Chemother. 2004, 54, 999–1006. [CrossRef] [PubMed]
30. Song, J.; Harry, J.; Eastman, R.; Oliver, B.; White, T. The Candida albicans Lanosterol 14-α-Demethylase (ERG11) Gene Promoter Is Maximally Induced after Prolonged Growth with Antifungal Drugs. Antimicrob. Agents Chemother. 2004, 48, 1136–1144. [CrossRef] [PubMed]
31. Liu, J.; Xia, J.; Nie, K.; Wang, F.; Deng, L. Outline of the biosynthesis and regulation of ergosterol in yeast. World J. Microbiol. Biotechnol. 2019, 35, 1–8. [CrossRef] [PubMed]
32. Müller, C.; Neugebauer, T.; Zill, P.; Lass-Flörl, C.; Bracher, F.; Binder, U. Sterol composition of clinically relevant Mucorales and changes resulting from posaconazole treatment. Molecules 2018, 23, 1218. [CrossRef] [PubMed]
33. Martel, C.; Parker, J.; Bader, O.; Weig, M.; Gross, U.; Warrilow, A.; Rolley, N.; Kelly, D.; Kelly, S. Identification and characterization of four azole-resistant erg3 mutants of Candida albicans. Antimicrob. Agents Chemother. 2010, 54, 4527–4533. [CrossRef] [PubMed]
34. Antunes, L.; Han, J.; Ferreira, R.; Lolić, P.; Borchers, C.; Finlay, B. Effect of antibiotic treatment on the intestinal metabolome. Antimicrob. Agents Chemother. 2011, 55, 1494–1503. [CrossRef] [PubMed]
35. Barko, P.; McMichael, M.; Swanson, K.; Williams, D. The gastrointestinal microbiome: A review. J. Vet. Int. Med. 2018, 32, 9–25. [CrossRef] [PubMed]
36. Ehrström, S.; Daroczy, C.; Rylander, E.; Samuelsson, C.; Johansson, U.; Anzén, B.; Pählson, C. Lactic acid bacteria colonization and clinical outcome after probiotic supplementation in conventionally treated bacterial vaginosis and vulvovaginal candidiasis. Microb. Infect. 2010, 12, 691–699. [CrossRef] [PubMed]
37. Fonzi, W.; Irwin, M. Isogenic Strain Construction and Gene Mapping in Candida albicans. Genetics 1993, 134, 717–728. [CrossRef] [PubMed]
38. Sanglard, D.; Ischer, F.; Monod, M.; Bille, J. Susceptibilities of Candida albicans Multidrug Transporter Mutants to Various Antifungal Agents and Other Metabolic Inhibitors. Antimicrob. Agents Chemother. 1996, 40, 2300–2305. [CrossRef] [PubMed]
39. Sanglard, D.; Ischer, F.; Monod, M.; Bille, J. Cloning of Candida albicans genes conferring resistance to azole antifungal agents: Characterization of CDR2, a new multidrug ABC transporter gene. Microbiology 1997, 143, 405–416. [CrossRef] [PubMed]
40. Szczepaniak, J.; Łukaszewicz, M.; Krasowska, A. Estimation of Candida albicans ABC Transporter Behavior in Real-Time via Fluorescence. Front. Microbiol. 2015, 6, 1382. [CrossRef] [PubMed]
41. Vida, T.; Emr, S. A new vital stain for visualizing vacuolar membrane dynamics and endocytosis in yeast. J. Cell Biol. 1995, 128, 779–792. [CrossRef] [PubMed]
42. Szczepaniak, J.; Cieslik, W.; Romanowska, A.; Musiol, R.; Krasowska, A. Blocking and dislocation of Candida albicans Cdr1p transporter by styrylquinolines. Int. J. Antimicrob. Agents 2017, 50, 171–176. [CrossRef] [PubMed]
43. Suchodolski, J.; Derczak, D.; Muraszko, J.; Panek, J.J.; Jeziorska, A. Fluconazole and Lipopeptide Surfactin Interplay During Candida albicans Plasma Membrane and Cell Wall Remodeling Increases Fungal Immune System Exposure. Pharmaceutics 2020, 12, 314. [CrossRef] [PubMed]
44. Singh, A.; MacKenzie, A.; Girnun, G.; Del Poeta, M. Analysis of sphingolipids, sterols, and phospholipids in human pathogenic Cryptococcus strains. J. Lipid Res. 2017, 58, 2017–2036. [CrossRef] [PubMed]